NCT07164560View on ClinicalTrials.gov

Exploratory Study of TRBC1/2-Targeted CAR-T Cell Therapy in Relapsed/Refractory Peripheral T-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2028

Conditions
Refractory/Recurrent Peripheral T-cell Lymphoma
Interventions
BIOLOGICAL

Anti-TRBC1 CAR-T cells

lentiviral vector-transducted peripheral blood-derived T cells to express anti-TRBC1 CAR

Trial Locations (1)

Unknown

RECRUITING

2nd Affiliated Hospital,School of Medicine,Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Ruijin Hospital

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT07164560 - Exploratory Study of TRBC1/2-Targeted CAR-T Cell Therapy in Relapsed/Refractory Peripheral T-Cell Lymphoma | Biotech Hunter | Biotech Hunter